Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
vaccine_innovation_prioritisation_strategy [2022/08/07 00:47]
liam [Personnel]
vaccine_innovation_prioritisation_strategy [2024/01/02 07:32] (current)
liam
Line 9: Line 9:
 ==== Microarray patches ==== ==== Microarray patches ====
  
-In May 2020, the VIPS Steering Committee selected and recommended three vaccine-related innovations to prioritize in order to increase uptake of [[vaccines]]. [[Microaray patches]] (MAPS) were identified as the highest priority (the other two were "heat-stable and controlled temperature chain qualified vaccines", and barcodes on primary packaging).((Vaccine Innovation Prioritisation Strategy (VIPS). (2021). //Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan// (p. 2). Gavi, the Vaccine Alliance. https://web.archive.org/web/20220806221838/https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf)) During the second half of 2020 and into 2021, the VIPS Working Group published a five-year plan to develop these MAPS.+In May 2020, the VIPS Steering Committee selected and recommended three vaccine-related innovations to prioritize in order to increase uptake of [[vaccines]]. [[Microarray patches]] (MAPS) were identified as the highest priority (the other two were "heat-stable and controlled temperature chain qualified vaccines", and barcodes on primary packaging).((Vaccine Innovation Prioritisation Strategy (VIPS). (2021). //Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan// (p. 2). Gavi, the Vaccine Alliance. https://web.archive.org/web/20220806221838/https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf)) During the second half of 2020 and into 2021, the VIPS Working Group published a five-year plan to develop these MAPS.
  
 MAPS are small devices that "consist of an array of hundreds to thousands of micro-projections on a patch or backing. These micro-projections can be coated with, or are composed of, vaccine in a dry formulation." After being applied to the skin, the vaccine payload is delivered into the dermis and/or epidermis of the skin, which are rich in [[antigen]]-presenting cells. The two main types of MAPS being developed are solid-coated and dissolving. MAPS are small devices that "consist of an array of hundreds to thousands of micro-projections on a patch or backing. These micro-projections can be coated with, or are composed of, vaccine in a dry formulation." After being applied to the skin, the vaccine payload is delivered into the dermis and/or epidermis of the skin, which are rich in [[antigen]]-presenting cells. The two main types of MAPS being developed are solid-coated and dissolving.
  
-A number of organizations are funding the development MAPS including the [[Bill & Melinda Gates Foundation]], [[Biomedical Advanced Research and Development Authority]] (BARDA), the U.S. [[Centers for Disease Control and Prevention]] (CDC), and the [[World Health Organization]] (WHO). Developing companies include [[pharmaceutical_companies:Micron Biomedical]], the [[University of Connecticut]], [[pharmaceutical_companies:Vaxess]], [[pharmaceutical_companies:Vaxxas]] and [[pharmaceutical_companies:Verndari]].+A number of organizations are funding the development of MAPS including the [[Bill & Melinda Gates Foundation]], [[Biomedical Advanced Research and Development Authority]] (BARDA), the U.S. [[Centers for Disease Control and Prevention]] (CDC), and the [[World Health Organization]] (WHO). Developing companies include [[pharmaceutical_companies:Micron Biomedical]], the [[University of Connecticut]], [[pharmaceutical_companies:Vaxess]], [[pharmaceutical_companies:Vaxxas]] and [[pharmaceutical_companies:Verndari]].
  
 VIPS estimates early pilot programs for MAPS will begin no earlier than 2026. VIPS estimates early pilot programs for MAPS will begin no earlier than 2026.
Line 19: Line 19:
 ===== Personnel ===== ===== Personnel =====
  
-^  VIPS Steering Committee((Vaccine Innovation Prioritisation Strategy. //VIPS Steering Committee members.// Gavi, the Vaccine Alliance. Retrieved August 6, 2022, from https://archive.ph/4ZbZG))  ^^ +^  VIPS Steering Committee((Vaccine Innovation Prioritisation Strategy. //VIPS Steering Committee members.// Gavi, the Vaccine Alliance. Retrieved August 6, 2022, from https://archive.ph/4ZbZG))  ^^^ 
-^ Name  ^ Affiliation  ^+^ Name  ^ Affiliation Role  ^ 
 +| [[Alejandro Cravioto]]  | [[Universidad Nacional Autónoma de México]]  | Professor; SAGE Chair  | 
 +| [[David Robinson]]  | [[Bill & Melinda Gates Foundation]]  | Deputy Director of Vaccine Development and Surveillance, Chemistry Manufacturing and Controls 
 +| [[Christopher Morgan]]  | [[Jhpiego]] and [[Burnet Institute]]  | Senior Technical Advisor (Immunization) and Honorary Senior Principal Research Fellow 
 +| [[David Kaslow]]  | [[PATH]]  | Vice president, Essential Medicines 
 +| [[Jean-Pierre Amorij]]  | [[UNICEF]] Supply Division  | Vaccine Technology Specialist 
 +| [[Jerome Kim]]  | [[International Vaccine Institute]]  | Director General 
 +| [[Jon Abramson]]  | [[Wake Forest School of Medicine]]  | Professor of Pediatric Infectious Diseases 
 +| [[Kelly Moore]]  | [[Vanderbilt University School of Medicine]]  | Adjunct Associate Professor of Health Policy 
 +| [[Mark Jit]]  | [[London School of Hygiene and Tropical Medicine]]  | Professor, Vaccine Epidemiology 
 +| [[Mark Papania]]  | [[Centers for Disease Control and Prevention]] (CDC) Global Immunization Division  | Medical Epidemiologist 
 +| [[Michael Free]]  | Independent  | Independent Consultant; Senior Advisor Emeritus, [[PATH]] 
 +| [[Nora Dellepiane]]  | [[QRB Consultants Sàrl]]  | Independent consultant 
 +| [[Ramanan Laxminarayan]]  | [[Center for Disease Dynamics, Economics and Policy]]  | Director 
 +| [[Ruth Karron]]  | [[Johns Hopkins University]]  | Professor, International Health 
 +| [[Samir Sodha]]  | [[World Health Organization]]  | Routine Immunization Officer 
 +| [[Shelley Deeks]]  | [[Public Health Ontario]]  | Chief Health Protection Officer  |
Back to top